Skip to main
ILMN

Illumina (ILMN) Stock Forecast & Price Target

Illumina (ILMN) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 27%
Buy 33%
Hold 27%
Sell 7%
Strong Sell 7%

Bulls say

Illumina is well-positioned to capture a share of this growing market. Additionally, the company's strong financial position, with over $3.7 billion in cash and short-term investments, provides a cushion against any potential challenges. Based on Illumina's strong clinical adoption and potential for future growth in this area, I have a positive outlook on the company's stock.

Bears say

Illumina is facing multiple challenges in terms of growth sustainability in the clinical consumables market, as they are already experiencing high growth but still need to meet investor expectations while facing competition from other companies. Furthermore, their long-term growth projections are based on pre-China and pre-Aca/Gov changes, and there are potential risks such as academic demand remaining weak and sales declining in China. Additionally, there is strong competition in the nextgen sequencing market and sustainability issues such as environmental footprint and human capital management that the company must address.

Illumina (ILMN) has been analyzed by 15 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 33% recommend Buy, 27% suggest Holding, 7% advise Selling, and 7% predict a Strong Sell.

This aggregate rating is based on analysts' research of Illumina and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Illumina (ILMN) Forecast

Analysts have given Illumina (ILMN) a Buy based on their latest research and market trends.

According to 15 analysts, Illumina (ILMN) has a Buy consensus rating as of Sep 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $201.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $201.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Illumina (ILMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.